MCID: OVR056
MIFTS: 28

Ovarian Primitive Germ Cell Tumor malady

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Ovarian Primitive Germ Cell Tumor

Aliases & Descriptions for Ovarian Primitive Germ Cell Tumor:

Name: Ovarian Primitive Germ Cell Tumor 12 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:5351
NCIt 47 C39986
UMLS 69 C1518727

Summaries for Ovarian Primitive Germ Cell Tumor

MalaCards based summary : Ovarian Primitive Germ Cell Tumor is related to eccrine papillary adenoma and rete testis adenoma. An important gene associated with Ovarian Primitive Germ Cell Tumor is AFP (Alpha Fetoprotein), and among its related pathways/superpathways are Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers and Ran Pathway. The drugs Cisplatin and Sodium thiosulfate have been mentioned in the context of this disorder. Related phenotypes are embryo and endocrine/exocrine gland

Related Diseases for Ovarian Primitive Germ Cell Tumor

Graphical network of the top 20 diseases related to Ovarian Primitive Germ Cell Tumor:



Diseases related to Ovarian Primitive Germ Cell Tumor

Symptoms & Phenotypes for Ovarian Primitive Germ Cell Tumor

MGI Mouse Phenotypes related to Ovarian Primitive Germ Cell Tumor:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 embryo MP:0005380 9.7 GPC3 MSX2 NKX2-5 SALL4 SIRT1 TEK
2 endocrine/exocrine gland MP:0005379 9.56 AFP EZH2 HLX HOXB7 KPNA1 MSX2
3 homeostasis/metabolism MP:0005376 9.36 AFP EZH2 GPC3 HLX KPNA1 KRT7

Drugs & Therapeutics for Ovarian Primitive Germ Cell Tumor

Drugs for Ovarian Primitive Germ Cell Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 169)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 3,Phase 1 15663-27-1 84093 441203 2767
2 Sodium thiosulfate Approved Phase 3
3
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
4
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757 53477783
5
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
6
Cyproheptadine Approved Phase 3 129-03-3 2913
7
Norgestimate Approved Phase 3 35189-28-7 6540478
8
Moxifloxacin Approved, Investigational Phase 3 354812-41-2, 151096-09-2 152946
9
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
10 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
11 Liver Extracts Phase 3,Phase 2,Phase 1
12 pancreatic polypeptide Phase 3
13 Analgesics Phase 3
14 Chelating Agents Phase 3,Phase 2
15
Serotonin Phase 3,Phase 2 50-67-9 5202
16 Adjuvants, Anesthesia Phase 3
17 Serotonin Agents Phase 3,Phase 2
18 Serotonin Antagonists Phase 3,Phase 2
19 Narcotics Phase 3
20 Gastrointestinal Agents Phase 3,Phase 2
21 Neurotransmitter Agents Phase 3,Phase 2
22 Dermatologic Agents Phase 3,Phase 2
23 Analgesics, Opioid Phase 3
24 Anesthetics Phase 3
25 Anesthetics, General Phase 3
26 Anesthetics, Intravenous Phase 3
27 Peripheral Nervous System Agents Phase 3,Phase 2
28 Anti-Bacterial Agents Phase 3,Phase 1
29 Anti-Infective Agents Phase 3,Phase 2,Phase 1
30 Protective Agents Phase 3,Phase 2,Phase 1
31 Antidotes Phase 3
32 Antitubercular Agents Phase 3
33 Antioxidants Phase 3
34 Central Nervous System Depressants Phase 3,Phase 2
35 Antipruritics Phase 3,Phase 2
36 Estradiol valerate Phase 3 979-32-8
37
Histamine Phosphate Phase 3 51-74-1 65513
38 Contraceptive Agents Phase 3
39 Contraceptives, Oral Phase 3
40 Contraceptives, Oral, Combined Phase 3
41 Norgestimate, ethinyl estradiol drug combination Phase 3
42 Nucleic Acid Synthesis Inhibitors Phase 3
43 Histamine Antagonists Phase 3
44 Histamine H1 Antagonists Phase 3
45 Anti-Allergic Agents Phase 3
46 Estradiol 17 beta-cypionate Phase 3
47 Estradiol 3-benzoate Phase 3
48 Polyestradiol phosphate Phase 3
49 Fluoroquinolones Phase 3
50 Cola Nutraceutical Phase 3,Phase 1,Phase 2

Interventional clinical trials:

(show top 50) (show all 66)
id Name Status NCT ID Phase
1 Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy Completed NCT00716976 Phase 3
2 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
3 A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families Completed NCT00782145 Phase 3
4 Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant Terminated NCT00324324 Phase 3
5 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3
6 Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation Unknown status NCT00036712 Phase 2
7 Temozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid Tumors Completed NCT00005952 Phase 1, Phase 2
8 Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors Completed NCT00024258 Phase 2
9 Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer Completed NCT00002515 Phase 2
10 High-dose ICE With Amifostine Completed NCT00003657 Phase 2
11 Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment Completed NCT00091182 Phase 2
12 Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect Completed NCT00003425 Phase 1, Phase 2
13 Lymphocyte Infusion in Treating Patients With Relapsed Cancer After Bone Marrow or Peripheral Stem Cell Transplantation Completed NCT00003887 Phase 2
14 Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors Completed NCT00004157 Phase 2
15 Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer Completed NCT00003408 Phase 2
16 Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon Completed NCT00010283 Phase 1, Phase 2
17 Campath-1H + FK506 and Methylprednisolone for GVHD Completed NCT00109993 Phase 2
18 Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation Completed NCT00064311 Phase 1, Phase 2
19 Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant Completed NCT00410657 Phase 2
20 Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant Completed NCT00795769 Phase 2
21 Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma Completed NCT00003308 Phase 2
22 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2
23 Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Active, not recruiting NCT00788125 Phase 1, Phase 2
24 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Active, not recruiting NCT00445965 Phase 2
25 Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant Terminated NCT00602446 Phase 2
26 Palifermin in Preventing Oral Mucositis Caused by Chemotherapy and/or Radiation Therapy in Young Patients Undergoing Stem Cell Transplant Withdrawn NCT00728585 Phase 2
27 Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors Unknown status NCT00007813 Phase 1
28 ABT-751 in Treating Young Patients With Refractory Solid Tumors Completed NCT00036959 Phase 1
29 Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors Completed NCT00303940 Phase 1
30 Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy Completed NCT00030108 Phase 1
31 Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors Completed NCT00020150 Phase 1
32 Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors Completed NCT00014456 Phase 1
33 Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors Completed NCT00003107 Phase 1
34 Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor Completed NCT00161187 Phase 1
35 MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma Completed NCT00020579 Phase 1
36 Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer Completed NCT00060372 Phase 1
37 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) Completed NCT00031681 Phase 1
38 Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia Completed NCT01484015 Phase 1
39 Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors Completed NCT00003597 Phase 1
40 Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors Completed NCT00019630 Phase 1
41 Thalidomide and Docetaxel in Treating Patients With Advanced Cancer Completed NCT00049296 Phase 1
42 Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal Cancer Completed NCT00436657 Phase 1
43 Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction Completed NCT00030498 Phase 1
44 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma Completed NCT00004241 Phase 1
45 Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors Completed NCT00089362 Phase 1
46 T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies Recruiting NCT02457650 Phase 1
47 Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors Terminated NCT00003926 Phase 1
48 Electroacupuncture in Treating Delayed Nausea and Vomiting in Patients Receiving Chemotherapy For Newly Diagnosed Childhood Sarcoma, Neuroblastoma, Nasopharyngeal Cancer, Germ Cell Tumors, or Hodgkin Lymphoma Completed NCT00040911
49 Development of Strategies to Increase Enrollment in Clinical Trials for Children With Cancer Completed NCT00002485
50 Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant Completed NCT00293384

Search NIH Clinical Center for Ovarian Primitive Germ Cell Tumor

Genetic Tests for Ovarian Primitive Germ Cell Tumor

Anatomical Context for Ovarian Primitive Germ Cell Tumor

Publications for Ovarian Primitive Germ Cell Tumor

Articles related to Ovarian Primitive Germ Cell Tumor:

id Title Authors Year
1
SALL4 is a novel sensitive and specific marker of ovarian primitive germ cell tumors and is particularly useful in distinguishing yolk sac tumor from clear cell carcinoma. ( 19295406 )
2009

Variations for Ovarian Primitive Germ Cell Tumor

Expression for Ovarian Primitive Germ Cell Tumor

Search GEO for disease gene expression data for Ovarian Primitive Germ Cell Tumor.

Pathways for Ovarian Primitive Germ Cell Tumor

Pathways related to Ovarian Primitive Germ Cell Tumor according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.26 AFP NKX2-5 SERPINA1
2 9.8 KPNA1 KPNA2

GO Terms for Ovarian Primitive Germ Cell Tumor

Cellular components related to Ovarian Primitive Germ Cell Tumor according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 ESC/E(Z) complex GO:0035098 8.62 EZH2 SIRT1

Biological processes related to Ovarian Primitive Germ Cell Tumor according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription from RNA polymerase II promoter GO:0000122 9.8 EZH2 MSX2 NKX2-5 SALL4 SIRT1
2 outflow tract septum morphogenesis GO:0003148 9.37 MSX2 NKX2-5
3 NLS-bearing protein import into nucleus GO:0006607 9.32 KPNA1 KPNA2
4 heart trabecula formation GO:0060347 9.26 NKX2-5 TEK
5 ovulation from ovarian follicle GO:0001542 9.16 AFP SIRT1
6 modulation by virus of host process GO:0019054 8.96 KPNA1 KPNA2
7 regulation of DNA recombination GO:0000018 8.62 KPNA1 KPNA2

Molecular functions related to Ovarian Primitive Germ Cell Tumor according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 sequence-specific DNA binding GO:0043565 9.43 EZH2 HLX HOXB7 MSX2 NKX2-5 SALL4
2 transcription factor binding GO:0008134 9.02 MSX2 NKX2-5 SALL4 SIRT1 SRY

Sources for Ovarian Primitive Germ Cell Tumor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....